Therefore, the key to the successful treatment of ALI/ARDS associated with sepsis, pneumonia, and COVID-19 may lie in modulating upstream NF-κB regulatory pathways such that augmented inflammatory signaling is reduced while critical homeostatic and repair mechanisms are maintained. This evidence concerns the gene NFKB1 and COVID-19.